• Explore /
  • Poster
  • / The efficacy and safety of the capecitabine/temozolomide (CAPTEM) regimen in the treatment of well-differentiated neuroendocrine tumors with liver metastasis after failure of previous therapy: Columbia University Medical Center experience.

The efficacy and safety of the capecitabine/temozolomide (CAPTEM) regimen in the treatment of well-differentiated neuroendocrine tumors with liver metastasis after failure of previous therapy: Columbia University Medical Center experience.

Abstract Poster

Authors

Paul Oberstein

Paul Oberstein

Columbia University Medical Center

Paul Oberstein , Anthony Gulati , Benjamin Krantz , Rebecca Moss , Stephen Schreibman , Dawn Tsushima , Kelley Mowatt , John Allendorf , Beth Schrope , James Lee , William Sherman , John Chabot , Robert Fine

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Citation

J Clin Oncol 31, 2013 (suppl 4; abstr308)

DOI

10.1200/jco.2013.31.4_suppl.308

Abstract #

308

Poster Bd #

C56

Abstract Disclosures

Similar Posters

First Author: Valeria Smiroldo

First Author: Robert Lance Fine

First Author: Thomas Aparicio

First Author: Alex Ganetsky